Published in Rheumatology (Oxford) on October 01, 2008
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia (2011) 1.26
Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis (2009) 1.13
Nuclear DNA sensor IFI16 as circulating protein in autoimmune diseases is a signal of damage that impairs endothelial cells through high-affinity membrane binding. PLoS One (2013) 0.89
Ocular findings in patients with systemic sclerosis. Clinics (Sao Paulo) (2011) 0.87
Pharmacotherapy of systemic sclerosis. Expert Opin Pharmacother (2010) 0.86
Vascular leak is a central feature in the pathogenesis of systemic sclerosis. J Rheumatol (2012) 0.85
Cardiovascular involvement in autoimmune diseases. Biomed Res Int (2014) 0.82
Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int (2014) 0.82
Circulating angiopoietin and Tie-2 levels in systemic sclerosis. Rheumatol Int (2012) 0.80
Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis. Stem Cells Int (2016) 0.78
Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. Clin Rheumatol (2014) 0.78
Engineering dextran-based scaffolds for drug delivery and tissue repair. Nanomedicine (Lond) (2012) 0.77
Infection and autoimmune disease. Rheumatol Int (2012) 0.77
Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis. Eur J Rheumatol (2016) 0.75
The challenges of dialysis in systemic sclerosis: between the devil and the deep blue sea? Case Rep Nephrol (2012) 0.75
Cellular Therapies in Systemic Sclerosis: Recent Progress. Curr Rheumatol Rep (2016) 0.75
The vascular microenvironment and systemic sclerosis. Int J Rheumatol (2010) 0.75
Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis. Clin Rheumatol (2016) 0.75
Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients. Rheumatol Int (2011) 0.75
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis (2007) 2.60
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) (2006) 2.44
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med (2001) 2.14
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis (2010) 1.73
Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med (2003) 1.71
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehabil (1997) 1.62
Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) (2009) 1.44
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
The measurement of outcome and the rheumatoid arthritis core set to lift the prejudice of the 'thaumaturgus cliche'. Rheumatology (Oxford) (2006) 1.42
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken) (2012) 1.40
High free and latent collagenase activity in psoriatic arthritis synovial fluids. Br J Rheumatol (1994) 1.39
Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. Arthritis Rheum (2001) 1.39
Suppression of autoantibodies to factor VIII and correction of factor VIII deficiency with a combined steroid-cyclophosphamide-porcine factor VIII treatment in a patient with rheumatoid arthritis. J Intern Med (1992) 1.38
Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis (2008) 1.32
The release of microparticles by apoptotic cells and their effects on macrophages. Apoptosis (2005) 1.32
Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol (1993) 1.30
Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) (2009) 1.29
Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis (2007) 1.26
Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. Rheumatology (Oxford) (2006) 1.24
Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis (2010) 1.22
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. Ann Rheum Dis (2008) 1.13
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) (2008) 1.12
Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum (2001) 1.11
Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford) (2008) 1.10
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis (2009) 1.09
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. Ann Rheum Dis (2009) 1.08
Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis (2011) 1.05
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis (2006) 1.05
Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis (2010) 1.05
Pulmonary arterial hypertension in systemic sclerosis: diagnostic pathway and therapeutic approach. Ann Rheum Dis (2005) 1.03
Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum (1995) 1.02
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant (2004) 1.01
Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis (2008) 1.00
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis (2008) 0.99
Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis. Ann Rheum Dis (2004) 0.99
Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum (2011) 0.98
NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet (2000) 0.98
Macrophage activation results in bone resorption. Clin Orthop Relat Res (1998) 0.97
Cutaneous fibrinolytic activity in primary hypertrophic osteoarthropathy. Scand J Rheumatol (1987) 0.97
Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum (2011) 0.96
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol (2010) 0.96
Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis (2008) 0.95
Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum (1999) 0.94
Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis (2004) 0.94
Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. Arthritis Rheum (2010) 0.94
The Italian version of the Mouth Handicap in Systemic Sclerosis scale (MHISS) is valid, reliable and useful in assessing oral health-related quality of life (OHRQoL) in systemic sclerosis (SSc) patients. Rheumatol Int (2011) 0.94
Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol (2009) 0.93
[Vascular changes in the pathogenesis of systemic sclerosis]. Z Rheumatol (2004) 0.92
Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum (1998) 0.92
Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol (1998) 0.92
Activation of the IL-4 STAT pathway in rheumatoid synovium. J Immunol (2000) 0.91
Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease. Autoimmunity (1990) 0.91
Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis (2010) 0.91
Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol (2006) 0.91
Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol (1998) 0.91
Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis (2007) 0.91
Neuropeptides of the autonomic nervous system in Sjögren's syndrome. Ann Rheum Dis (1997) 0.91
Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis (2002) 0.90
Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) (2006) 0.90
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis (2007) 0.89
[Rheumatoid arthritis: new developments in the pathogenesis with special reference to synovial fibroblasts]. Z Rheumatol (2001) 0.89
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis (2008) 0.89
Non organ based laboratory markers in systemic sclerosis. Clin Exp Rheumatol (2003) 0.88
The rehabilitation of facial involvement in systemic sclerosis: efficacy of the combination of connective tissue massage, Kabat's technique and kinesitherapy: a randomized controlled trial. Rheumatol Int (2010) 0.88
Severe fibrotic changes and altered expression of angiogenic factors in maternal scleroderma: placental findings. Ann Rheum Dis (2009) 0.88
Circulating leptin levels in juvenile idiopathic arthritis: a marker of nutritional status? Ann Rheum Dis (2005) 0.88
Differential adherence of osteoarthritis and rheumatoid arthritis synovial fibroblasts to cartilage and bone matrix proteins and its implication for osteoarthritis pathogenesis. Scand J Immunol (2004) 0.87
HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. Arthritis Rheum (2000) 0.87
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford) (2008) 0.87
Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis (2008) 0.87
Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol (2001) 0.86
Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol (2001) 0.86
Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis. Rheumatology (Oxford) (2006) 0.85
Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology (Oxford) (2006) 0.84
Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways. Ann Rheum Dis (2004) 0.83
Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis (2006) 0.83
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis. Ann Rheum Dis (2008) 0.83
Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma). J Rheumatol (2000) 0.83
High levels of substance P in rheumatoid arthritis synovial fluid. Lack of substance P production by synoviocytes in vitro. Clin Exp Rheumatol (1991) 0.82
Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int (2011) 0.82
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.82
Effect of melatonin on normal and sclerodermic skin fibroblast proliferation. Clin Exp Rheumatol (1997) 0.81
Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial. Aliment Pharmacol Ther (2007) 0.81
Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database. Ann Rheum Dis (2005) 0.81
Effect of substance P and somatostatin on migration of polymorphonuclear (PMN) cells in vitro. Inflammation (1992) 0.81
Primary antiphospholipid syndrome: a report of two pediatric cases. J Rheumatol (1991) 0.81
Pregnancy in systemic sclerosis. Rheumatology (Oxford) (2008) 0.81
Reflex sympathetic dystrophy in children. J Child Neurol (1999) 0.80
Pregnancy outcome in systemic lupus erythematosus complicated by anti-phospholipid antibodies. Rheumatology (Oxford) (2008) 0.80
Iliopsoas bursitis in rheumatoid arthritis. Clin Exp Rheumatol (1994) 0.80